期刊
CHIMIA
卷 64, 期 1-2, 页码 8-13出版社
SWISS CHEMICAL SOC
DOI: 10.2533/chimia.2010.8
关键词
Anticancer; Azathilones; Drug discovery; Epothilones; Natural product synthesis
资金
- Swiss National Science Foundation [200021-107876, 205320-117594]
- ETH Zurich
- Novartis Pharma AG
Epothilones are bacterial macrolides with potent microtubule-stabilizing and anti proliferative activity, which have served as successful lead structures for the discovery of several clinical candidates for cancer treatment. Overall, seven epothilone-type agents have been advanced to clinical evaluation in humans so far and one of these has been approved by the FDA in 2007 for clinical use in breast cancer patients. Notwithstanding these impressive numbers, however, the structural diversity represented by the collection of epothilone analogs that have been (or still are) investigated clinically is rather limited and their individual structures show little divergence from the original natural product leads. In contrast, we have elaborated a series of epothilone-derived macro-lactones, whose overall structural features significantly deviate from those of the natural epothilone scaffold and thus define new structural families of microtubule-stabilizing agents. Key elements of our hypermodification strategy are the change of the natural epoxide geometry from cis to trans, the incorporation of conformationally constrained side chains, the removal of the C(3)-hydroxyl group, and the replacement of C(12) with nitrogen. The latter modification leads to aza-macrolides that may be described as 'non-natural natural products'.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据